Daratumumab, Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Capecitabine, Temozolomide, Pemetrexed, Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Rucaparib, Regorafinib, Enzalutamide, Sunitinib
Cancer
Recruiting
Pan Tumor Rollover Study